Summary
2LB Chart
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Igor Bilinsky - Chief Operating Officer Friedrich Graf Finckenstein - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Salim Syed Nicholas Lorusso - TD Cowen, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2025 Conference Call.
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play
Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $100 million in annual costs, extending its cash runway and supporting continued pipeline development despite ongoing heavy losses. The rejection of a key competitor's therapy by the FDA boosts IOVA's market prospects, but profitability remains uncertain due to high costs and slow revenue ramp.
Iovance Biotherapeutics, Inc. (2LB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Iovance Biotherapeutics, Inc. ever had a stock split?
Iovance Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Frederick G. Vogt CEO | XBER Exchange | US4622601007 ISIN |
| US Country | 838 Employees | - Last Dividend | 26 Sep 2013 Last Split | 15 Oct 2010 IPO Date |
Overview
Iovance Biotherapeutics, Inc. stands as a commercial-stage biotechnology entity dedicated to developing and commercializing innovative cell therapies. Utilizing autologous tumor infiltrating lymphocyte technology, the company aims to provide treatments for metastatic melanoma alongside other solid tumor cancers within the United States. Originating in 2007 and originally known as Lion Biotechnologies, Inc., the company transitioned to its current name in June 2017. With its headquarters in San Carlos, California, Iovance Biotherapeutics has established numerous strategic collaborations and licensing agreements with prominent institutions and companies across the healthcare and biotechnology sectors. These partnerships extend to WuXi Advanced Therapies, Inc.; National Institutes of Health; National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH, aiming to enhance its offering and impact in cancer treatment.
Products and Services
- Amtagvi
Described as a pioneering tumor-derived autologous T cell immunotherapy, Amtagvi is specifically designed for adult patients struggling with unresectable or metastatic melanoma. This product marks Iovance's commitment to offering advanced therapeutic options that leverage the body's immune system to fight cancer.
- Proleukin
An interleukin-2 product, Proleukin serves as a treatment solution for patients with metastatic renal cell carcinoma. Through boosting the patient's immune response, it aims at attacking and eliminating cancer cells, underscoring the company's expertise in immunotherapy.
- Lifileucel in combination with pembrolizumab
This development focuses on treating frontline advanced melanoma patients by combining lifileucel with pembrolizumab. The strategic integration of these treatments exemplifies Iovance's innovative approach towards providing comprehensive care for melanoma patients.
- LN-145
Targeted at addressing the challenges in non-small cell lung cancer (NSCLC) and other solid tumor cancers, LN-145 is an ongoing project that aims to expand the therapeutic reach of the company’s immunotherapy solutions.
- IOV-4001
Currently in Phase 1/2 IOV-GM1-201 clinical trial, IOV-4001 represents Iovance's commitment to innovating treatment options for NSCLC. This exploration into new therapies highlights the company’s dedication to contributing significant advancements in cancer treatment.
- Lifileucel for Gynecological Cancers
Another pivotal area of development, the application of lifileucel for treating gynecological cancers, signifies Iovance's broader endeavor to tackle a variety of cancer types with its cell therapy technologies.
Contact Information
